Researchers Karijn Suijkerbuijk

Karijn Suijkerbuijk

Full Professor

Strategic program(s):

Biography

Karijn Suijkerbuijk is a translational medical oncologist with special interest in melanoma and immunotherapy. During her PhD, she performed research on tumor epigenetics in breast cancer in the lab of Professor Saraswati Sukumar at the Sidney Kimmel Cancer Center at Johns Hopkins University. Dr. Suijkerbuijk currently participates in multiple phase II and III clinical trials on immune checkpoint inhibitors. She published papers in Oncogene, Annals of Oncology and JNCI, received research grants from KWF and NWO and was awarded an ASCO Merit Award. Her current research focuses on clinical and immunological parameters assoaciated with immune related adverse events during checkpoint inhibition and clinicopathological factors associated with checkpoint inhibitor response.

Strategic program(s):

Contact

ksuijke2@umcutrecht.nl

Pure profile

Research groups

Molecular and cellular host-microbiota interactions

Research aim

Our research aims to unravel how the products from pathogenic and beneficial bacterial species within the intestinal microbiota contribute to human health and disease.

Go to group

Immunotherapy in solid tumors

Research aim

Our research aims at accomplishing cure and good quality of life for more and more patients with metastatic cancer by: - AI-based early identification of (non-)responders to current immunotherapy - new immunotherapies for non-responders - developing strategies to treat immunotherapy toxicity without compromising efficacy

Go to group

Recent publications

All publications

Validation of 11 added items of the outpatient version of the Utrecht Symptom Diary in patients receiving chemotherapy or targeted therapy Josephine J Koldenhof, Bernice O Akpobome, Danielle Zweers, Stance Klaasse, Saskia C C M Teunissen, Petronella O Witteveen, Karijn P M Suijkerbuijk, Alexander de Graeff, Frederieke H van der Baan
Journal of patient-reported outcomes, 2024, vol. 8

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients Daan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza, Remco van Doorn, Jos van der Hage, A J M van den Eertwegh, John B Haanen, Maureen J B Aarts, Franchette W P J van den Berkmortel, Christiaan U Blank, Marye J Boers-Sonderen, Jan Willem B de Groot, Geke A P Hospers, Djura Piersma, Rozemarijn S van Rijn, A M Stevense-den Boer, Astrid A M van der Veldt, Gerard Vreugdenhil, Michel W J M Wouters, Karijn P M Suijkerbuijk, Ellen Kapiteijn
Cancers, 2024, vol. 16

Adjuvant treatment with anti-PD-1 in acral melanoma Manja Bloem, Olivier J. van Not, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Willeke A.M. Blokx, Marye J. Boers-Sonderen, Johannes J. Bonenkamp, Jan Willem B. de Groot, John B. Haanen, Geke A.P. Hospers, Ellen W. Kapiteijn, Melissa M. de Meza, Djura Piersma, Rozemarijn S. van Rijn, Marion A.M. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Alfons J.M. van den Eertwegh, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters
International Journal of Cancer, 2024, vol. 155, p.1455-1465

Improving survival in advanced melanoma patients Olivier J van Not, Alfons J M van den Eertwegh, John B Haanen, Christian U Blank, Maureen J B Aarts, Jesper van Breeschoten, Franchette W P J van den Berkmortel, Jan-Willem B de Groot, Geke A P Hospers, Rawa K Ismail, Ellen Kapiteijn, Manja Bloem, Melissa M De Meza, Djura Piersma, Rozemarijn S van Rijn, Marion A M Stevense-den Boer, Astrid A M van der Veldt, Gerard Vreugdenhil, Marye J Boers-Sonderen, Willeke A M Blokx, Michel W J M Wouters, Karijn P M Suijkerbuijk
EClinicalMedicine, 2024, vol. 69, p.1-10

Long-Term Survival in Patients With Advanced Melanoma Olivier J van Not, Alfons J M van den Eertwegh, University Groningen, Manja Bloem, John B Haanen, Rozemarijn S van Rijn, Maureen J B Aarts, Franchette W P J van den Berkmortel, Christian U Blank, Marye J Boers-Sonderen, Jan Willem de Groot J W B, Geke A P Hospers, Ellen Kapiteijn, Brenda Leeneman, Piersma D, Marion Stevense-den Boer, Astrid A M van der Veldt, Gerard Vreugdenhil G, Michel W J M Wouters, Willeke A M Blokx, Karijn P M Suijkerbuijk
JAMA network open, 2024, vol. 7

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma Lindsay V M Leek, Jessica C L Notohardjo, Karlijn de Joode, Eline L Velker, John B A G Haanen, Karijn P M Suijkerbuijk, Maureen J B Aarts, Jan Willem B de Groot, Ellen Kapiteijn, Franchette W P J van den Berkmortel, Hans M Westgeest, Tanja D de Gruijl, Valesca P Retel, Edwin Cuppen, Astrid A M van der Veldt, Mariette Labots, Emile E Voest, Joris van de Haar, Alfons J M van den Eertwegh
Scientific Reports, 2024, vol. 14

External positions

research funding Genmab - AI onderzoekssamenwerking in Health Holland project dat door Genmab financieel wordt ondersteund - Genmab

ESMO Melanoma Faculty Chair - melanoomexpertise - European Society for Medical Oncology

Scientific Steering Committee ESMO 2024 (melanoma track chair) - melanoom expertise - European Society for Medical Oncology

ESMO melanoma faculty - expertise melanoom - European Society for Medical Oncology

Lid real world data working group ESMO - onderzoek patientcohorten - European Society for Medical Oncology

Lid wetenschappelijke adviesraad - ervaring onderzoek - Maarten van der Weijden foundation

Adviesraad stichting melanoom (sinds 2019) - Vanuit expertise als melanoombehandelaar - Stichting melanoom

Lid Data Safety Monitoring Committee CHOPIN studie (vanaf 2020; studie gesponsord door BMS) - onderzoekservaring immuuntherapie - LUMC

Voorzitter wetenschappelijke commissie - Kwaliteitsverbetering en onderzoek op het gebied van melanoomzorg - Dutch Melanoma Treatment Registry (DICA)

Adviesgroep kanker in de zwangerschap - Expertise melanoom en immuuntherapie - Adviesgroep kanker in de zwangerschap

Onderzoeksfinanciering UNICIT-project door Bristol Myers Squibb - onderzoek immuuntherapie - UMC Utrecht

Organisatie/voorzitter jaarlijks immuno-oncologie symposium - expertise en onderzoek immuunoncologie - Immuno-oncologie symposium

Bestuurslid Tumorfocusgroep melanoom - expertise melanoom - Tumorfocusgroep melanoom

medisch expert bij melanoom nascholing en congresjournaal ASCO/ESMO - expertise melanoom - Medtalks